Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Also known as COREG CR, COREG
COREG and lisinopril · 4 trials · 1 indication
| Name | Type | Description |
|---|---|---|
| COREG CR and lisinopril (FDC) | DRUG | - |
| COREG CR | DRUG | - |
| Lisinopril | DRUG | - |
Inclusion criteria: * Healthy volunteer Adult males and females of non-child bearing potential who are between 18 to 55 years of age, inclusively * Body weight \> 60 kg (132 lbs) and body mass index (BMI) between 19 and 33 Exclusion criteria: * Any clinically relevant abnormality identified on th...
Top 9 of 16 competitors
| Company | Ticker | Trials | Lead Phase | Drugs |
|---|---|---|---|---|
| AstraZeneca PLC | AZN | 5 | PHASE3 | Baxdrostat |
| Eli Lilly and Company | LLY | 4 | PHASE3 | Orforglipron, Clazakizumab |
| Alnylam Pharmaceuticals, Inc | ALNY | 2 | PHASE3 | Zilebesiran, ALN-AGT01 RVR |
| Mineralys Therapeutics, Inc. | MLYS | 1 | PHASE3 | lorundrostat |
| United Therapeutics Corporation | UTHR | 1 | PHASE3 | Ralinepag |
| Novartis AG Sponsored ADR | NVS | 3 | PHASE2 | QCZ484, HJB647 |
| Vanda Pharmaceuticals Inc. | VNDA | 1 | PHASE2 | iloperidone |
| Opus Genetics, Inc. | IRD | 1 | PHASE1 | OPGx-BEST1 |
| CRISPR Therapeutics AG | CRSP | 1 | PHASE1 | CTX340 |
COREG and lisinopril refers to a fixed dose combination product candidate that pairs COREG CR, the extended release form of carvedilol, with lisinopril. It is being developed for hypertension, also known as high blood pressure, and is a small molecule combination therapy. The program is being advanced by GSK plc.
COREG and lisinopril is being developed for the treatment of hypertension. The fixed dose combination is intended to combine COREG CR, an extended release beta blocker, with lisinopril, an ACE inhibitor, in a single product. It remains investigational and is not approved for use in hypertension.
COREG and lisinopril is being developed by GSK plc, which trades under the ticker GSK. GSK is the sponsor of the clinical program evaluating the fixed dose combination of COREG CR and lisinopril for hypertension.
COREG and lisinopril is in Phase 1 clinical development. All four of its recorded trials are Phase 1 studies, and all four are completed. No active trials are ongoing. The program is investigational and has not been approved for any indication.
COREG and lisinopril has been studied in four completed Phase 1 trials: NCT00557128, which examined the effect of food on pharmacokinetics; NCT00556920, which assessed bioequivalence to its components; NCT00552708, which investigated bioequivalence of the fixed dose combination; and NCT00549510, which investigated dose proportionality.
No. COREG and lisinopril is a fixed dose combination product that pairs COREG CR with lisinopril. COREG CR on its own is the extended release form of carvedilol and is one component of the combination. The combination is also referred to as COREG CR and lisinopril (FDC).